Still trail­ing far be­hind a block­buster ri­val, No­var­tis gath­ers an­oth­er round of pos­i­tive sur­vival da­ta for Kisqali

Just two months ago, No­var­tis’ team turned up at AS­CO with some clear­ly pos­i­tive im­proved sur­vival rates for a group of pre-menopausal breast can­cer pa­tients tak­ing the CDK 4/6 drug Kisqali. And now they’re back, say­ing they al­so scored in a sep­a­rate tri­al track­ing OS among an­oth­er group of post-menopausal women tak­ing the block­buster wannabe.

We won’t hear the de­tails on the Monaleesa-3 da­ta un­til they can be rolled out lat­er at a sci­en­tif­ic con­fer­ence, but in­ves­ti­ga­tors say the drug scored on the key end­point in first-line and sec­ond-line cas­es. And this ex­pands on their boast for hold­ing the first — though no longer the on­ly — pos­i­tive sur­vival re­sults in the field, some­thing No­var­tis on­col­o­gy chief Su­sanne Schaf­fert says she’s “thrilled” to see.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.